SCHEMBL2964331

SCHEMBL2964331

COc1ccc(CNS(=O)(=O)c2ccc3snc(Cl)c3c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
CYP19A1 P11511 1/20 0.51
TSHR P16473 3/20 0.50
LMNA P02545 2/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CNR1 P21554 1/20 0.47
RAB9A P51151 1/20 0.47
KDM4E B2RXH2 1/20 0.47
MAPK1 P28482 1/20 0.47
USP2 O75604 1/20 0.47
ILK Q13418 1/20 0.46
THRB P10828 1/20 0.45
RECQL P46063 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2965486 0.80 ALDH1A1 (0.47) ALDH1A1CYP19A1TSHRLMNAHTT
SCHEMBL22230051 0.76 ILK (0.63) ALDH1A1CYP19A1TSHRLMNAHTT
SCHEMBL15390183 0.74 LMNA (0.60) ALDH1A1CYP19A1TSHRLMNAHTT
SCHEMBL2969558 0.74 KMT2A (0.51) ALDH1A1TSHRHTTKDM4ERECQL
SCHEMBL18740699 0.73 EPAS1 (0.42) ALDH1A1TSHRHTTRAB9AKDM4E
SCHEMBL9942089 0.72 POLB (0.73) ALDH1A1CYP19A1TSHRLMNAHTT
SCHEMBL13310570 0.71 ALDH1A1 (0.78) ALDH1A1CYP19A1TSHRLMNAHTT
SCHEMBL19636581 0.71 ALDH1A1 (1.00) ALDH1A1CYP19A1TSHRLMNAHTT
SCHEMBL12793674 0.71 ALDH1A1 (0.78) ALDH1A1CYP19A1TSHRLMNAHTT
SCHEMBL14419665 0.70 ALDH1A1 (0.67) ALDH1A1CYP19A1TSHRLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776847-B2 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2010-08-17 US disclosed
US-7776847-B2 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2010-08-17 US disclosed
US-7776847-B2 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2010-08-17 US disclosed
EP-1853573-A1 BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION Rigel Pharmaceuticals, Inc. (US) 2007-11-14 EP disclosed
US-20060229294-A1 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2006-10-12 US disclosed
WO-2006091858-A1 BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION RIGEL PHARMACEUTICALS, INC. (US) 2006-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229294-A1 Benzisothiazoles useful for treating or preventing HCV infection HAVCR2, ZC3HAV1, MAVS ALDH1A1 227/4885CYP19A1 2234/4885TSHR 4487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.